Supplemental material
Journal of Market Access & Health Policy
Volume 5, 2017 - Issue 1
Article
Healthcare resource use in schizophrenia, EuroSC findings
, , , , & 
M. ToumiPublic Health Department, Aix-Marseille University, Francehttp://orcid.org/0000-0001-7939-7204View further author information
http://orcid.org/0000-0001-7939-7204View further author informationRelated Research Data
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Source:
ELSEVIER SCIENCE BV
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
Source:
Springer Nature
Réflexion sur la péréquation financière de psychiatrie en France
Source:
Elsevier BV
Negative Symptoms of Schizophrenia as Primary Target of Cognitive Behavioral Therapy: Results of the Randomized Clinical TONES Study
Source:
Oxford University Press (OUP)
Findings From the CLAMORS Study
Source:
Physicians Postgraduate Press, Inc
Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores
Source:
Elsevier BV
An economic evaluation of a contingency-management intervention for stimulant use among community mental health patients with serious mental illness
Source:
Elsevier BV
Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
Source:
Springer Nature
A prospective study of Quality of life in schizophrenia in three European countries
Source:
Elsevier BV
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
Source:
Springer Science and Business Media LLC
Urban residence, victimhood and the appraisal of personal safety in people with schizophrenia: results from the European Schizophrenia Cohort (EuroSC).
Source:
Cambridge University Press (CUP)
Linking provided by
